| Name | Title | Contact Details |
|---|
Alliance Machine Systems International LLC is the global source of innovative products and services to enhance the efficiency and performance of the corrugated packaging industry. The company continuously strives to provide customers with an ever-broadening line of products and services through investments in R&D, training, strategic acquisitions and partnerships. For more than 40 years, Spokane Valley, Washington-based Alliance has designed and manufactured more than 14,000 machines for the corrugated industry, with installations worldwide. Alliance offers material handling systems that keep pace with todays faster finishing machines. It offers high-speed feeding and downstream handling designs that are reliable, cost-effective solutions to increasing productivity. Products include robotic loadformers, stackers, prefeeders, pallet handlers, specialty folder gluers, and more.
Arq is a diversified, environmental technology company with products that enable a cleaner and safer planet while actively reducing our environmental impact.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.